The increasing complexity of large molecule therapeutics has driven the need for additional approaches to quantitation in regulated bioanalysis where challenges with traditional ligand binding assays (LBA) are encountered for PK assay establishment. Hybrid immunoaffinity/mass spectrometry (IA/MS) techniques have been able to provide solutions such as improved selectivity, sensitivity, and the ability to multiplex measurements. This combination of techniques offers the advantages of specific antibody-antigen interactions together with the selectivity provided by the multiple dimensions of separation with liquid chromatography and mass spectrometry (LC−MS).
Download Document
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Automation within an ADME Laboratory
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
